When patients with schizophrenia initiate second-generation antipsychotic therapy, clinicians commonly monitor weight as an early warning sign of metabolic harm. However, findings from a recent electronic health record study of adults suggest that blood glucose levels may rise soon after treatment begins, underscoring the need for earlier glucose monitoring in this population.